Christopher R. Cline, CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 573 shares at $18.20 ($11K) on 2025-09-03, disclosed to the SEC on 2025-09-05.
Scheduled sale ($11k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.20 | 454 | $8K | 77.9% |
| 2 | $19.71 | 119 | $2K | 22.1% |
| Total | $18.51 avg | 573 | $11K | 100% |
| Filing → |
| TVTX | SELL | 2026-05-06 | $115K | — | Filing → |
| TVTX | SELL | 2026-04-15 | $349K | — | Filing → |
| TVTX | SELL | 2026-02-05 | $56K | — | Filing → |